On May 29th, 2013, GlaxoSmithKline (GSK) announced the acquisition of Okairos in an all-cash deal worth $325 million US. The Okairos acquisition helps complement the pharma giant's existing vaccine technology and expertise and will enable GSK to continue its work developing the next g

Montreal-based Caprion has established itself as a leader in the proteomic biomarker discovery field, using its proteomics discovery platform CellCarta® to develop pharmacodynamic biomarkers, disease markers and predictive biomarkers. OneMedRadio spoke with Caprion President and CEO M

MicroRNA’s are very small endogenous, non-coding, oligonucleotides. They are implicated in regulating a broad range of biological processes. These are molecules which are involved in important regulation of biological processes, and the potential of using these molecules as targets fo

Investors and company executives may be "shocked" to learn that the chronic wound market size is estimated at $20 billion, according to AdvaMed. Alpharetta, Ga.-based SanuWave (SNWV) looks to reduce that sticker shock. The company is developing potentially game-changing extracorp re

In Part II of our interview with Vijay Aggarwal, Managing Partner of the Channel Group, we explore trends in the space, reimbursement issues, and the state of equity financing. Dr. Aggarwal also discusses changing investment strategy with regards to evaluating risk factors, a more sop

In case you missed it, Monday featured a number of interesting developments in the world of healthcare and life sciences. Most notably, a seemingly rare patent defeat may harm Novartis' bottom line in India, but helps secure a mass population to a popular leukemia drug. India has emer

What if there was a way to substantially reduce high blood pressure for patients who have tried everything? Renal denervation is a hot topic, and ReCor Medical offers a unique ultrasound approach to enhance this exciting therapy…

OneMedRadio spoke with Clinova, a British pharmaceutical company focused on developing, manufacturing and marketing consumer healthcare products and medical device, has a rare global presence in multiple emerging markets, while also securing a significant market presence in Europe.

Young's experience in both sectors makes him a unique voice in the osmosis of venture capital between mobile technology and life sciences. Young will participate in a panel dedicated to the subject at the 6th Annual OneMedForum in San Francisco, January 7-9. OneMedRadio spoke with Jac

OneMedPlace announced today that Peter Neupert of Health Evolution Partners and Jack Young of Qualcomm Ventures will participate in programming for the 6th Annual OneMedForum, January 7-9, 2013, in San Francisco. The two experts will take part in a panel dedicated to ‘Digital and Conn

Last week, OneMedRadio spoke with Immune Pharmaceuticals founder and CEO Dr. Daniel Teper and Epicept Corporation President and CEO Robert Cook, to discuss the merger and the clinical focus of the merged company going forward.

Fallout from the the US Supreme Court landmark decision to deny two patents to Prometheus Laboratories may complicate the future profitability of the industry. If this is indeed a precedent-setting decision, biomarker patents may now fall under the realm of “law of nature”, cutting of

This is Part II of our special report on the state of immunotherapy in the public markets. This report looks at promising anticancer immunotherapy technologies, and the major issues in bringing these technologies to the general public.

Hosted by BioNJ, Pennsylvania Bio and Delaware Bio, their three word mission: “Find. Fund. Facilitate.” was clearly accomplished. Networking is still an integral part of these cerebral gatherings, however programming at this conference provided attendees with candid information, stim

CEVEC Pharmaceuticals GmbH (CEVEC), the developer of a novel human expression system for the manufacturing of complex biopharmaceuticals and vaccines announced today that it raised an additional amount of € 2.8 million in a Series C financing led by Peppermint VenturePartners (PVP) vi